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Trends in cholesterol testing in general 
practice
Schouten, J André Knottnerus, Richard PTM GrolTrudy van der Weijden, Ron AG Winkens, Berna J
Objectives: To assess trends in die ordering of choles­
terol tests by general practitioners (GPs), and to assess 
whether the trend in ordering cholesterol tests is con­
sistent with the recommendations in the Dutch guide­
lines for GPs.
Methods: Analysis of total cholesterol and lipid fraction 
tests at the Maastricht diagnostic centre, which serves 
all 85 GPs in the region* over the years 1984-1992.
Main outcome measures are the number of cholesterol, 
HDL, LDL and triglyceride tests per year, and the num­
ber of cholesterol tests per GP per year. The frequency 
of cholesterol and lipid fraction testing in ‘new patients’ 
(patients presenting for cholesterol testing for the first 
time) are indicators for adherence to the guidelines on 
the diagnostic procedure. Data on new patients were 
available for the years 1989-1992.
Results: There was an overall increase in the total num­
ber of cholesterol tests of 173% between 1984 and 
1992. There is considerable and stable inter-doctor 
variation. In new patients, 13.5% of male and 23,0% 
of female patients did not fulfil the age criteria accord­
ing to the national guidelines. Repeat testing regarding 
diagnosis of hypercholesterolaemia as recommended 
was not performed in 86% of the new patients in 1989, 
which increased to 94% in 1992. Lipid fraction testing 
during the first contact with a new patient was not 
recommended; nevertheless this was done in 38% of 
the cases in 1989, decreasing to 31% in 1992. 
Conclusions: The strong increase in the number of 
cholesterol tests ordered over the years was accom-
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panied by a large and sustained inter-doctor variation 
in cholesterol testing. The diagnostic procedure 
improved slightly for lipid fraction testing, but deteri­
orated for repeat testing. Improvement on these topics 
should be sought, to prevent non-rational cholesterol 
management, which can have a relevant impact on the 
GP’s workload and the resources of the public health 
system. In pursuing improvement, more attention 
should be given to effective implementation strategies 
as well as to the scientific validity of the guidelines. 
EurJ Gen Pract 1996'; 2: 148-52.
Introduction
Important developments on the cholesterol issue took 
place in the 1980s. Results of large cholesterol interven­
tion studies were published, the HMG coenzyme-A reduc­
tase inhibitors were introduced, quickly followed by cho­
lesterol guidelines for all Dutch physicians.1’4 These devel­
opments, and the ongoing debate about the controversial 
character of cholesterol testing, have raised questions 
whether a specific trend in GPs’ behaviour in ordering cho­
lesterol tests has developed over the last decade.5'7
Specific guidelines for cholesterol management in the gen­
eral practice setting were published by the Dutch College 
of GPs in November 1991/ Caution with regards to test­
ing characterises these guidelines; selective case finding is 
only indicated for people aged 18-65 years with an unfa­
vourable coronary risk profile. Diagnosis of hypercholes­
terolaemia requires the mean of three serum cholesterol 
tests to be higher than 6.5 mmol/L Determination of HDL 
and triglycerides is only indicated if cholesterol-lowering 
drugs are being considered.
Considerable discrepancy between usual care and the 
guidelines was reported for Dutch GPs before publication 
of these guidelines/3 Simply disseminating cholesterol 
guidelines does not change daily practice.10,11 To promote 
implementation of new guidelines, more insight into ac­
tual behaviour of GPs is required. In many countries a low 
adherence to cholesterol guidelines by GPs has been re­
ported.12'1* A study of possible trends in ordering choles­
terol tests will further explore the relation between usual 
care and the guidelines. It might improve insight into pos­
sible external factors that have the power to influence GPs 
in their cholesterol management, or factors that restrain 
GPs from working according the guidelines.
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The need for information on trends in the ordering of cho­
lesterol tests regarding implementation of the guidelines, 
together with the controversial character of cholesterol 
testing over the years, stimulated us to address the follow­
ing questions:
1 What is the trend in cholesterol and lipid fraction test­
ing in general practice over the period 1984-1992, and 
which patients are being tested?
2 What is the trend in diagnostic performance in relation 
to the guidelines for selective case finding, repeat test­
ing and lipid fraction testing?
Methods
Materials
Data were used from the Diagnostic Coordinating Centre 
Maastricht (DCC). Since 1979, this centre has processed 
all diagnostic requests of GPs (about 85) in Maastricht and 
surroundings, covering a region with 187,000 inhabitants. 
All requests have been stored in a computerised database 
which provides a good opportunity to describe time trends. 
Every day these GPs ‘refer’ 125-150 patients to the dia­
gnostic centre; that is, 30,000-35,000 patients yearly. A 
standardised form is used for diagnostic requests. Only tests 
requested regularly are printed on the form. Cholesterol 
and triglycerides are printed, while high density lipopro­
teins (HDL) and low density lipoproteins (LDL), if request­
ed, have to be written on the form by the GPs themselves. 
The GPs are also invited to register clinical data on the pa­
tient and the reason for the request.
Trends in cholesterol testing
To analyse the volume of test ordering in the course of 
time, the total number of tests per year for cholesterol, tri­
glycerides, HDL and LDL were extracted from the data­
base. The age and sex characteristics, the reasons for re­
quest, as well as the prevalence of hypercholesterolaemia 
were analysed in all patients. An increase in compliance
Figure 1. Trend in total number of cholesterol and lipid fraction 
tests at the Diagnostic Coordinating Centre Maastricht, 1984-1992.
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with the recommendations specified by the Dutch guide­
lines should subsequently result in a decreased in ter-doc­
tor variation in ordering tests. For a trend analysis of in­
ter-doctor variation in ordering cholesterol tests, GPs who 
had not been participating for the whole year were ex­
cluded, still leaving an average of S I GPs per year for this 
analysis. Due to skewed distribution, inter-doctor vari­
ation was not expressed using means and standard devi­
ations, but using the median (= quartile 2) and quartiles 1 
and 3 as indicators for inter-doctor variation. A higher in­
ter-doctor variation, expressed as the distance between 
quartile 1 (Ql) and quartile 3 (Q3), may just be the con­
sequence of an increasing median. Therefore we corrected 
the inter-doctor variation for the higher median by calcu­
lating the ratio (Q3-Ql)/median.
Trends in diagnostic performance related to the guidelines 
According to the national guidelines, cholesterol testing 
in 'new patients7 (patients presenting for the first time for 
cholesterol testing) should be restricted to people aged 
between 18 and 65 years. Technical advances made it pos­
sible to identify the subgroup of new patients for the years 
1989-1992. The age and sex distribution of this subgroup, 
repetition of cholesterol testing, as well as the frequency 
of triglyceride and HDL testing were analysed. Repeat 
testing is indicated for patients with a cholesterol value 
higher than 4.9 mmol/1. Proper repeat testing in 6 weeks' 
time was described, in addition to a milder variant: at least 
one repetition of cholesterol testing in 6 months1 time. As 
lipid fraction testing is only indicated if cholesterol-low­
ering drugs are being considered, there should not be an 
indication for HDL or triglyceride testing in new patients. 
Instead of taking a sample, full population data of the 
diagnostic centre could be used; statistical testing was not 
indicated.
Results
Trends in cholesterol testing
Figure 1 illustrates the trend in the total number of total 
cholesterol, HDL, LDL and triglyceride tests in the Maas­
tricht region. There was an increase of 219% in choles­
terol testing in the period 1984-1990, which stabilised and 
slightly decreased by 21% in the period 1990-1992, result­
ing in an overall increase of 173% between 1984-1992. 
There were no clear trends in triglyceride and HDL-cho- 
lesterol testing. Triglyceride testing was performed about 
three times more often than HDL testing in this period. 
LDL testing was hardly observed.
The age and sex distribution of the patients tested did not 
change during the nine-year period. Fifty-three percent of 
the patients tested were male (mean age 49 years, SD 12.9); 
the mean age of female patients was 55 years (SD 13.6). 
The prevalence of hypercholesterolaemia was already high 
in 1984 (51%), increased to 63% in 1987 and then de­
creased to 45% in 1992.
The inter-doctor variation for the number of serum cho­
lesterol tests per year is illustrated in figure 2. There is con­
siderable inter-doctor variation which, in absolute num-
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Figure 2. Trend in inter-doctor variation of cholesterol testing per
GP, 1984-1992.
Median (=quartile 2) of number of tests per GP; quartile 1 (Q l) and 
quartile 3 (Q3) indicating inter-doctor variation
bers, seems to have increased during the nine-year period. 
However, although rhe ratio (Q3-Ql)/median remains 
higher than 1.0 throughout the period, there was no clear 
increasing or decreasing trend in this ratio.
Trends in diagnostic performance related to the guidelines 
The age and sex distribution of the new patients (patients 
presenting for cholesterol testing for the first time) did not 
change during this four-year period (table 1). On average 
55% of the new patients were male, 13,5% of whom were 
not in the 18-65 age range which is the first criterion for 
selective case finding. Of the new female patients 23.0% 
did not fulfil the 18-65 age criterion.
Table 2 illustrates the number of tests used to diagnose hy­
percholesterolaemia per new patient per year. Proper dia­
gnosis of hypercholesterolaemia was performed in 0.3- 
0.4% of the new patients. In 1989,13.7% of these patients 
had at least two cholesterol tests in a period of six months, 
which decreased to 6.4% of the patients in '1992. Figure
3 illustrates that in 1989, GPs requested HDL and trigly­
ceride testing in 38% of new patients, which is not indic­
ated according to the guidelines. This lipid fraction testing 
in new patients decreased to 31 % in 1992.
Discussion
Cholesterol testing by GPs affiliated to the Maastricht dia­
gnostic centre increased by 173% in the period 1984- 
1992. Inter-doctor variation remained high, even after sta­
bilisation of the increase in testing in 1990, despite publica­
tion of Dutch cholesterol guidelines in 1987 and 1991. 
There is considerable discrepancy between behaviour in 
ordering cholesterol tests and the guidelines. It is remark­
able that, while the evidence on the benefits of choles­
terol lowering is less for women than for men, relatively 
more women (23%) than men (13.5%) of 65 years and 
older are tested.17 The poor and even deteriorating perform­
ance on repeat testing, which has also been reported else­
where, is alarming because insufficient repeat testing will 
impair the precision of diagnoses and the cost-effectiveness 
of cholesterol testing.l!Uy Many forces seem to influence 
GPs1 behaviour in ordering cholesterol tests, despite the 
guidelines. Patients actively requesting cholesterol testing 
might be one of the important determinants of GPs1 be­
haviour in this field, as one in every five cholesterol tests 
were initiated by the patient in 1992 (the only year in 
which valid data could be collected on this aspect).
It is clear that cholesterol testing is taking up far more of 
GPs’ time and attention than 10 years ago. The high preval­
ence of hypercholesterolaemia gives an indication of the 
impact of cholesterol testing on the workload of GPs, be­
cause established hypercholesterolaemia consequently im­
plies intervening activities.
Due to large amounts of missing clinical data on the test 
ordering form, no analyses could be done with the patient’s 
coronary risk profile or reasons for request. The strength 
of the study is the quality of the data source; considering 
the high number of participating practices and the fact that 
no apparent shifts have occurred, the population was very 
stable throughout the years.20 The participating GPs were 
comparable to other Dutch GPs, except for the fact that 
GPs served by the Diagnostic Centre Maastricht have been 
provided twice yearly with individual feedback on selected 
behaviour in ordering tests (there has been no structural 
feedback on cholesterol diagnosis until now).2lul The vol­
ume of ordering these selected tests, as well as tests on
1989 1990 1991 1992 mean
C? 9 9 c? 9 9 a 9
Sex 54 46 54 46 55 45 55 45 55 45
<18 or >65 yrs 13 24 13 22 13 24 15 23 13.5 23.0
Total new patients: 2616 3131 2439 2131
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1989 1990 1991 1992
One test only 86.3 86.3 89.0 93 6
> 1 test in 6 months 13.3 13.4 10.7 6.1
Repeat testing according to the guidelines* 0.4 0.3 0.3 0.3
i— i l l , ai  — ----------------------------------------------------------------------- ---------  ------------ -— i -----------------  u m n ^ i  ■ n  v u j j . . . . ______n n _____________ l i j ___________________________________________________________________ i_______ i________i_________________ ______________ i________ j i _____________________ _ _ j ________i ____.___ ■ i  ____i r t n ____ r ~ _ t t
New patients with cholesterol >4.9 mmol/1 2249 2591 1941 1667
* Diagnosis of hypercholesterolemia requires the mean of three serum cholesterol tests, determined m a period of six weeks, to be higher than 6 5 mmol/!. 
If the first test-value is lower than 5.0 mmol/I, or the mean of two values is lower than 6.5 mmol/!, there is no indication for (further) repetition of testing
which no feedback was given, decreased compared to a ref­
erence diagnostic centre. The reference diagnostic centre 
showed a much steeper increase in cholesterol testing of 
377% over the years 1984-1990, with a comparable sta­
bilisation in 1990. Therefore the trend found at the Maas­
tricht diagnostic centre seems to be an underestimation of 
the trends found in other Dutch diagnostic centres.
What are the implications of the results for implementa­
tion of the guidelines? The discrepancy between behaviour 
in ordering cholesterol tests and the guidelines does not 
necessarily mean a low quality of care. Guidelines imply 
little performance measurement, as medical practice re­
mains fundamentally an interpersonal experience, draw­
ing on the rich interaction between practitioner and pa­
tient.22 Physicians cite barriers for adherence to the guide­
lines such as: limitations in time, reimbursement, motiva­
tion and skills.2*'25 Based on the barriers to change, a com­
plex programme for improvement that meets prevailing 
administrative and reimbursement policies,2* is needed 
with a mix of several strategies for implementation; e.g. 
individualised feedback on GPs’ behaviour in ordering 
tests, in combination with strategies such as an adjustment 
of the forms for ordering tests, peer discussions in small
Figure 3. Trend in the proportion of HDL and/or triglyceride testing 
in new patients, having a first cholesterol measurement, 1989-1992.
groups, or outreach visits from academically-qualified rep­
resentatives or local opinion leaders.2 10 To increase the 
likelihood of the guidelines changing medical practice, the 
feasibility of the guidelines should be discussed at local 
level/ 1
In addition to a discussion on the implementation of the 
guidelines, the results prompt a critical look at the scient­
ific validity of the guidelines. The ongoing debate about 
which high-risk groups benefit most by cholesterol screen­
ing needs clarification. It is remarkable that the practice 
guidelines that have been published internationally are 
conflicting in several aspects. Cholesterol guidelines seem 
to be influenced more by moral and economic factors than 
by evidence of health benefit. The method of develop­
ing the guidelines determines the scientific validity of the 
guidelines.54 ’1' Recently, a method for grading health care 
recommendations was proposed in which both scientific 
validity and cost-effectiveness considerations (number of 
patients that need to be treated) are combined.36’"
We conclude that the strong increase in the number of cho­
lesterol tests ordered over the years was not accompanied 
by a decrease in inter-doctor variation and improvement in 
quality of testing. We recommend that improvement on 
these topics should be sought, to prevent non-rational cho­
lesterol management. In pursuing improvement, more at­
tention should be given to effective implementation strat­
egies as well as to the scientific validity of the guidelines.
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